CEO Ramon Laguarta said the Doritos maker hasn’t seen a “direct impact” from GLP-1 medications despite a higher level of awareness among consumers toward health and wellness.

As expected, PepsiCo ( PEP) saw business disruptions across certain markets due to international conflicts and geopolitical tensions, factors which are expected to persist in 2025. Management's commentary on the impact of weight loss drugs indicates that the company may look to add more healthy snacks to its portfolio.

PepsiCo is also closely watching a longer-term trend toward healthier snacking, Laguarta said. The company isn’t seeing much impact from the growing use of GLP-1 weight loss dru